UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 212

Sortiert nach

Impact of Using A Mixed Data Collection Modality on Statistical Inferences in Decentralized Clinical Trials

Therapeutic innovation & regulatory science, 2022-09, Vol.56 (5), p.744-752

2022

Volltextzugriff (PDF)

Analysis of a Binary Outcome Dichotomized from an Underlying Continuous Variable in Clinical Trials

Therapeutic innovation & regulatory science, 2023-09, Vol.57 (5), p.1008-1016

2023

Volltextzugriff (PDF)

Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic

Therapeutic innovation & regulatory science, 2021-09, Vol.55 (5), p.984-988

2021

Volltextzugriff (PDF)

Accurate Collection of Reasons for Treatment Discontinuation to Better Define Estimands in Clinical Trials

Therapeutic innovation & regulatory science, 2023-05, Vol.57 (3), p.521-528

2023

Volltextzugriff (PDF)

Proportion of treatment effect mediated by surrogate endpoints

Biometrical journal, 2021-01, Vol.63 (1), p.105-121

2021

Volltextzugriff (PDF)

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin―Treated Patients With Type 2 Diabetes

Diabetes care, 2012-11, Vol.35 (11), p.2140-2147

2012

Volltextzugriff (PDF)

Non-monotone Exponential Time (NEXT) Model for the Longitudinal Trend of a Continuous Outcome in Clinical Trials

Therapeutic innovation & regulatory science, 2024, Vol.58 (1), p.127-135

2024

Volltextzugriff (PDF)

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

Diabetes care, 2013-03, Vol.36 (3), p.522-528

2013

Volltextzugriff (PDF)

Can a multiple ascending dose study serve as an informative proof‐of‐concept study?

Statistics in medicine, 2019-02, Vol.38 (3), p.354-362

Qu, Yongming

2019

Volltextzugriff (PDF)

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

Diabetes care, 2010-05, Vol.33 (5), p.951-957

2010

Volltextzugriff (PDF)

Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes

The American journal of medicine, 2010-05, Vol.123 (5), p.468.e9-468.e17

2010

Volltextzugriff (PDF)

Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study

Journal of bone and mineral research, 2005-09, Vol.20 (9), p.1514-1524

2005

Volltextzugriff (PDF)

Lower Glucose Variability and Hypoglycemia Measured by Continuous Glucose Monitoring With Novel Long-Acting Insulin LY2605541 Versus Insulin Glargine

Diabetes care, 2014-03, Vol.37 (3), p.659-665

2014

Volltextzugriff (PDF)

Sample size calculation for the Wilcoxon-Mann-Whitney test adjusting for ties

Statistics in medicine, 2008-02, Vol.27 (3), p.462-468

2008

Volltextzugriff (PDF)

Return‐to‐baseline multiple imputation for missing values in clinical trials

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2022-05, Vol.21 (3), p.641-653

2022

Volltextzugriff (PDF)

Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: A randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study

Clinical therapeutics, 2008-05, Vol.30 (5), p.858-867

2008

Volltextzugriff (PDF)

Evaluation of a surrogate marker: validity and efficiency

Statistics in medicine, 2013-05, Vol.32 (12), p.1995-2000

Qu, Yongming

2013

Volltextzugriff (PDF)

Propensity score estimation with missing values using a multiple imputation missingness pattern (MIMP) approach

Statistics in medicine, 2009-04, Vol.28 (9), p.1402-1414

2009

Volltextzugriff (PDF)

The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety

Menopause (New York, N.Y.), 2007-05, Vol.14 (3 Pt 1), p.510

2007

Volltextzugriff (PDF)

Estimation of group means using Bayesian generalized linear mixed models

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2020-07, Vol.19 (4), p.482-491

2020

Volltextzugriff (PDF)

Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia

Metabolism, clinical and experimental, 2006-07, Vol.55 (7), p.972-979

2006

Volltextzugriff (PDF)

Quantifying the indirect treatment effect via surrogate markers

Statistics in medicine, 2006-01, Vol.25 (2), p.223-231

2006

Volltextzugriff (PDF)

Using principal stratification in analysis of clinical trials

Statistics in medicine, 2022-08, Vol.41 (19), p.3837-3877

2022

Volltextzugriff (PDF)

Restricted Time Win Ratio: From Estimands to Estimation

Statistics in biopharmaceutical research, 2024-04, p.1-19

2024

Volltextzugriff (PDF)

Understanding and adjusting for the selection bias from a proof‐of‐concept study to a more confirmatory study

Statistics in medicine, 2020-12, Vol.39 (30), p.4593-4604

2020

Volltextzugriff (PDF)

1 – 25 von 212

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(150)
Mit Volltextzugriff
(196)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(132)
Life Sciences & Biomedicine
(101)
Physical Sciences
(67)
Humans
(63)
Mathematics
(47)
Statistics & Probability
(46)
Female
(34)
Technology
(31)
Pharmacology & Pharmacy
(30)
Mathematical & Computational Biology
(26)
Medicine, Research & Experimental
(24)
Research & Experimental Medicine
(24)
Clinical Trials
(23)
Male
(22)
Middle Aged
(22)
Medical Informatics
(20)
Data Interpretation, Statistical
(19)
Endocrinology & Metabolism
(19)
Treatment Outcome
(19)
Engineering
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Impact of Using A Mixed Data Collection Modality on Statistical Inferences in Decentralized Clinical Trials

Analysis of a Binary Outcome Dichotomized from an Underlying Continuous Variable in Clinical Trials

Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic

Accurate Collection of Reasons for Treatment Discontinuation to Better Define Estimands in Clinical Trials

Proportion of treatment effect mediated by surrogate endpoints

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin―Treated Patients With Type 2 Diabetes

Non-monotone Exponential Time (NEXT) Model for the Longitudinal Trend of a Continuous Outcome in Clinical Trials

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

Can a multiple ascending dose study serve as an informative proof‐of‐concept study?

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes

Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study

Lower Glucose Variability and Hypoglycemia Measured by Continuous Glucose Monitoring With Novel Long-Acting Insulin LY2605541 Versus Insulin Glargine

Sample size calculation for the Wilcoxon-Mann-Whitney test adjusting for ties

Return‐to‐baseline multiple imputation for missing values in clinical trials

Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: A randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study

Evaluation of a surrogate marker: validity and efficiency

Propensity score estimation with missing values using a multiple imputation missingness pattern (MIMP) approach

The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety

Estimation of group means using Bayesian generalized linear mixed models

Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia

Quantifying the indirect treatment effect via surrogate markers

Using principal stratification in analysis of clinical trials

Restricted Time Win Ratio: From Estimands to Estimation

Understanding and adjusting for the selection bias from a proof‐of‐concept study to a more confirmatory study

Suchergebnisse filtern